×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

GLP-1R¼¤¶¯¼ÁµÄ·ÖÀà

2023-10-31
|
»á¼ûÁ¿£º

ƾ֤GLP-1R×÷ÓÃʱ¼ä£¬GLP-1R¼¤¶¯¼Á¿ÉÒÔ·ÖΪ¶ÌЧºÍ³¤Ð§Á½´óÀà¡£

Based on their ability to activate GLP-1 receptor£¬GLP-1 receptor agonists can be classified as short- acting and long-acting GLP-1R agonist.

¶ÌЧGLP-1R ¼¤¶¯¼Á£¬ÐèÒªÖðÈÕÒ»´Î»òÕßÖðÈÕÁ½´Î¸øÒ©¡£

Short-acting GLP-1R agonists are required to give either a once daily (QD) or twice-daily£¨BID£©dosing.

Èç°¬ÈûÄÇëĺÍÀûÎ÷À­ëĵÈ£¬³¤Ð§GLP-1R¼¤¶¯¼ÁÊǶԻ¯ºÏÎï·Ö×Ó¾ÙÐÐÁËһЩ½á¹¹ÐÞÊΣ¬ÕâÑù¿ÉÒÔÔöÇ¿Æä×÷ÓÃʱ¼ä£¬Í¬Ê±±£´æÆä×÷ÓÃÓÚGLP-1R µÄÄÜÁ¦.Èç¶ÅÀ­Â³ëÄ¡¢°¢±ØÂ³ëĵÈ£¬Ã¿ÖܸøÒ©Ò»´Î¼´¿É¡£

For example Exenatide and Lixisenatide, long acting GLP-1R agonists have undergone some structural modifications to enhance their duration of action while retaining their ability to act on the GLP-1 receptors. For example Albiglutide,Dulaglutide, once weekly.

¸ü¶à¡°GLP-1¡±×ÊѶ

¡¾Æ½Ì¨¡¿¡°GLP-1¡±ÐÂÒ©Ñз¢Ð§ÀÍÆ½Ì¨

¡¾ÊÓÆµ¡¿GLP-1 ×÷ÓûúÖÆ

¡¾ÊÓÆµ¡¿GLP-1s µÄÐÄÀí×÷ÓÃ

¡¾ÊÓÆµ¡¿ÒȸßѪÌÇËØÑùëÄ-1(GLP-1s) ÏÈÈÝ

¡¾ÐÂÎÅ¡¿GLP-1ÈÃ×¢Éä³ÔÒ©Ò²Äܼõ·Ê³ÉΪÏÖʵ

¡¾ÊÓÆµ¡¿Õë¶ÔNASH·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎÓÐÄÄЩ²î±ðµÄÐÂÒ©ÀàÐÍ

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿